HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

Press/Media

Period	8 Jun 2021

Media coverage

Title	HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
Media name/outlet	PipelineReview
Country/Territory	Spain
Date	8/06/21
URL	www.pipelinereview.com/index.php/2021060878395/Vaccines/HOOKIPA-Phase-1-HB-200-data-show-unprecedented-T-cell-response-favorable-tolerability-and-preliminary-efficacy-as-monotherapy-for-advanced-HPV16-cancers.html
Persons	Dmitriy Zamarin